查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485268

肺纖維化生物標記市場- 依測試類型（血液檢查、影像學檢查、肺活體組織切片）、適應症（特發性肺纖維化、塵肺病、結節病）、最終用戶（醫院、診斷實驗室） - 全球預測2024 - 2032

Pulmonary Fibrosis Biomarkers Market - By Test Type (Blood Test, Imaging Test, Lung Biopsy), Indication (Idiopathic Pulmonary Fibrosis, Pneumoconiosis, Sarcoidosis), End-user (Hospitals, Diagnostic Laboratories) - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於該領域的研究和開發不斷增加，2024 年至 2032 年間，全球肺纖維化生物標記市場規模的複合年成長率將達到 4.4%。隨著對肺纖維化的了解加深，對能夠準確診斷疾病、監測其進展和預測治療結果的生物標記的需求不斷成長。例如，2023 年 11 月，基因泰克公司的研究人員在一群科學家的帶領下，努力尋找特發性肺纖維化 (IPF)（一種嚴重肺部疾病）的生物標記。他們的重點在於探索生物活性脂質是否具有預測 IPF 進展的潛力。基因泰克公司的資深科學家 Margaret Neighbors 透露，他們最初的研究工作集中在慢性阻塞性肺病（COPD）。

先進的生物標記物能夠實現早期檢測和個人化治療策略，從而改善患者護理和預後。此外，正在進行的研究工作正在發現具有潛在診斷和預後效用的新型生物標記物，從而推動市場成長。隨著全球肺纖維化負擔的加重以及對精準醫療的日益重視，對可靠生物標記的需求預計將繼續成長，從而塑造肺纖維化生物標記市場的未來。

整個肺纖維化生物標記行業根據測試類型、適應症、最終用戶和地區進行分類。

血液檢測領域將在 2024 年至 2032 年期間經歷突破性發展。隨著研究不斷發現與疾病嚴重程度和預後相關的新型血液生物標記物，對可靠血液檢測的需求正在增加。醫療保健提供者擴大將基於血液的生物標記測試納入其診斷演算法中，推動了肺纖維化生物標記市場的擴大，並為與這種使人衰弱的肺部疾病作鬥爭的患者帶來改善結果的希望。

The pulmonary fibrosis biomarkers share from the drug induced pulmonary fibrosis segment will register a noteworthy CAGR from 2024 to 2032. As adverse drug reactions continue to pose a significant concern, there is a pressing need for biomarkers that can accurately detect and monitor drug-induced lung受傷.這些生物標記在識別高風險患者、實現早期介入和促進個人化治療方法方面發揮著至關重要的作用。隨著旨在識別與藥物引起的肺纖維化相關的特定生物標記的持續研究工作，對創新診斷工具的需求不斷增加，推動肺纖維化生物標記市場的成長並改善患者護理結果。

歐洲肺纖維化生物標記市場將在2024年至2032年呈現出值得稱讚的複合年成長率。準確檢測和監測疾病進展的生物標記的需求不斷增加。歐洲監管機構也鼓勵開發和採用基於生物標記的診斷工具，進一步推動市場成長。因此，歐洲的肺纖維化生物標記市場正在顯著擴張，為製造商和研究人員滿足該地區不斷變化的醫療保健需求提供了有利可圖的機會。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 肺纖維化盛行率上升
      • 生物標記發現技術不斷進步
      • 不斷增加的政府措施和政策
      • 增加生物標記的使用
    • 產業陷阱與挑戰
      • 與生物標記測試和診斷相關的高成本
      • 嚴格的監管場景
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析
  • 未來市場趨勢

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣

第 5 章：市場估計與預測：按測試類型，2018 年 - 2032 年

  • 主要趨勢
  • 驗血
    • C反應蛋白測試
    • 抗體檢測試劑盒
      • 抗核抗體（ANA）測試
      • 抗CCP抗體檢測
    • ESR 測試和 CBC
    • 肺功能檢查
    • 影像學檢查
      • X 光掃描
      • HRCT 掃描
    • 肺活體組織切片
    • 其他測試類型

第 6 章：市場估計與預測：按指標分類，2018 年 - 2032 年

  • 主要趨勢
  • 特發性肺纖維化（IPF）
  • 類風濕性關節炎間質性肺病 (RA-ILD)
  • 藥物性肺纖維化
  • COVID-19相關的肺纖維化
  • 塵肺
  • 結節病
  • 其他適應症

第 7 章：市場估計與預測：按最終用戶分類，2018 年 - 2032 年

  • 主要趨勢
  • 醫院
  • 專科診所
  • 診斷實驗室
  • 研究與學術機構
  • 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Biocartis NV
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffman-La Roche Ltd
  • Galapagos NV
  • Lung Therapeutics, Inc.
  • Myriad Genetics, Inc.
  • OptiKira LLC
  • Respivant Sciences GmbH
  • Veracyte, Inc.
簡介目錄
Product Code: 8456

Global Pulmonary Fibrosis Biomarkers Market Size will witness 4.4% CAGR between 2024 and 2032 due to rising research and developments in the field. As understanding of pulmonary fibrosis deepens, there is a growing need for biomarkers that can accurately diagnose the disease, monitor its progression, and predict treatment outcomes. For instance, in November 2023, researchers at Genentech Inc., spearheaded by a team of scientists, were endeavoring to identify biomarkers for idiopathic pulmonary fibrosis (IPF), a severe lung disease. Their focus lies in exploring whether bioactive lipid species hold potential in predicting the progression of IPF. Margaret Neighbors, a senior scientist at Genentech, revealed that their initial research efforts were centered on chronic obstructive pulmonary disease (COPD).

Advanced biomarkers enable early detection and personalized treatment strategies, improving patient care and prognosis. Moreover, ongoing research efforts are uncovering novel biomarkers with potential diagnostic and prognostic utility, driving market growth. With the global burden of pulmonary fibrosis on the rise and a growing emphasis on precision medicine, the demand for reliable biomarkers is expected to continue growing, shaping the future of the Pulmonary Fibrosis Biomarkers Market.

The overall Pulmonary Fibrosis Biomarkers Industry is classified based on the test type, indication, end-user, and region.

The blood test segment will undergo groundbreaking development from 2024 to 2032. Blood-based biomarkers offer a non-invasive and accessible means of assessing pulmonary fibrosis progression, aiding in treatment decision-making and patient management. As research continues to identify novel blood biomarkers associated with disease severity and prognosis, the demand for reliable blood tests is escalating. Healthcare providers are increasingly incorporating blood-based biomarker testing into their diagnostic algorithms, fueling the expansion of the Pulmonary Fibrosis Biomarkers Market and offering hope for improved outcomes for patients battling this debilitating lung condition.

The pulmonary fibrosis biomarkers share from the drug induced pulmonary fibrosis segment will register a noteworthy CAGR from 2024 to 2032. As adverse drug reactions continue to pose a significant concern, there is a pressing need for biomarkers that can accurately detect and monitor drug-induced lung injury. These biomarkers play a crucial role in identifying patients at risk, enabling early intervention, and facilitating personalized treatment approaches. With ongoing research efforts aimed at identifying specific biomarkers associated with drug-induced pulmonary fibrosis, the demand for innovative diagnostic tools is on the rise, driving growth in the Pulmonary Fibrosis Biomarkers Market and improving patient care outcomes.

Europe pulmonary fibrosis biomarkers market will showcase a commendable CAGR from 2024 to 2032. With a rising prevalence of pulmonary fibrosis cases and a need for early diagnosis and targeted treatment, there is a heightened demand for biomarkers that can accurately detect and monitor the disease progression. European regulatory bodies are also encouraging the development and adoption of biomarker-based diagnostic tools, further fueling market growth. As a result, the Pulmonary Fibrosis Biomarkers Market in Europe is witnessing significant expansion, presenting lucrative opportunities for manufacturers and researchers to address the region's evolving healthcare needs.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data sources
    • 1.5.1 Primary
    • 1.5.2 Secondary
      • 1.5.2.1 Paid sources
      • 1.5.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of pulmonary fibrosis
      • 3.2.1.2 Increasing advancements in biomarker discovery technologies
      • 3.2.1.3 Rising government initiatives and policies
      • 3.2.1.4 Increasing use of biomarkers
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with biomarker tests and diagnostics
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Blood test
    • 5.2.1 C-reactive protein test
    • 5.2.2 Antibody testing kits
      • 5.2.2.1 Antinuclear antibodies (ANA) test
      • 5.2.2.2 Anti-CCP antibody test
    • 5.2.3 ESR test and CBC
    • 5.2.4 Pulmonary function test
    • 5.2.5 Imaging test
      • 5.2.5.1 X-rays scans
      • 5.2.5.2 HRCT scans
    • 5.2.6 Lung biopsy
    • 5.2.7 Other test types

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Idiopathic pulmonary fibrosis (IPF)
  • 6.3 Rheumatoid arthritis interstitial lung disease (RA-ILD)
  • 6.4 Drug-induced pulmonary fibrosis
  • 6.5 COVID-19-related pulmonary fibrosis
  • 6.6 Pneumoconiosis
  • 6.7 Sarcoidosis
  • 6.8 Other indications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Diagnostic laboratories
  • 7.5 Research & academic institutes
  • 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Biocartis NV
  • 9.2 Biogen Inc.
  • 9.3 Bristol-Myers Squibb Company
  • 9.4 F. Hoffman-La Roche Ltd
  • 9.5 Galapagos NV
  • 9.6 Lung Therapeutics, Inc.
  • 9.7 Myriad Genetics, Inc.
  • 9.8 OptiKira LLC
  • 9.9 Respivant Sciences GmbH
  • 9.10 Veracyte, Inc.